Cyprotex Discovery

Cyprotex is a premier contract research organization (CRO) specializing in ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) and DMPK services. Established in 1999 and acquired by Evotec in 2016, the company supports the pharmaceutical, biotechnology, and chemical industries with high-quality in vitro and in silico data. Its service portfolio includes high-throughput ADME screening, mechanistic toxicology, and advanced predictive modeling using proprietary technologies like CellCiphr and Cloe PK. Cyprotex operates state-of-the-art facilities in Alderley Park, UK, and Framingham, USA, providing critical insights that help researchers optimize drug candidates and reduce late-stage attrition. The company is recognized for its expertise in early-stage drug safety and its ability to integrate complex biological data into actionable discovery programs. As a wholly-owned subsidiary of Evotec, Cyprotex continues to operate under its own brand while leveraging the global resources of its parent company.